跳至主要内容
临床试验/NCT03716245
NCT03716245已完成不适用

A Multicenter, Randomised, Open-label Prospective Clinical Trial to Evaluate the Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer Patients With Ipsilateral Supraclavicular Lymph Node Metastasis

Xinhong Wu, PhD1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2019年2月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
180
试验地点
1
主要终点
Disease free survival

研究概览

简要总结

Breast cancer patients with ipsilateral supraclavicular lymph node metastasis are defined as Ⅲc stage (N3) according to the newly published 8th AJCC TNM staging system. No concret guide line was supported to such patients. It is still pending whether to exert supraclavicular lymph node dissection to breast cancer patients with ipsilateral supraclavicular lymph node metastasis.

To evaluate the clinical significance and complication of supraclavicular lymph node dissection for breast cancer patients with ipsilateral supraclavicular lymph node metastasis, the investigators randomize patients into two groups, one group is supraclavicular lymph node dissection with radiotherapy group, the other group is radiotherapy group.

详细描述

Breast cancer is the most common cancer and the leading cause of deaths from cancer in women worldwide. Breast cancer patients with ipsilateral supraclavicular lymph node metastasis are defined as Ⅲc stage (N3) according to the newly published 8th AJCC TNM staging system. Clinical outcomes are similar for patients with ipsilateral supraclavicular lymph node metastases at first presentation and for patients with recurrent ipsilateral supraclavicular lymph node metastases. The survival rate was lower in patients with ipsilateral supraclavicular lymph node metastases than in patients with lower axillary or subclavian nodal involvement. No concrete guide line was supported to such patients. It is still pending whether to exert supraclavicular lymph node dissection to breast cancer patients with ipsilateral supraclavicular lymph node metastasis. Patients with ipsilateral supraclavicular lymph node metastases who were treated with surgery or radiotherapy and achieved good neck control were reported to achieve better survival than those for whom surgical treatment or irradiation did not result in good local control.

Patients with ipsilateral supraclavicular lymph node metastases should be offered a combined modality approach, including systemic therapy, surgery, and radiotherapy. Furthermore, local treatment, usually including axillary and supraclavicular lymph node, either by surgical clearance or by radical radiotherapy, can prevent the tumor cells from drainage, might be play a more important role. However, the role of surgical removal of the supraclavicular nodes is uncertain compared with radical radiotherapy. To our knowledge, the available literature comparing these two local treatments of ipsilateral supraclavicular lymph node metastases is scarce. Furthermore, the studies comparing the outcome of dissection of supraclavicular lymph node combined with local radiotherapy and radiotherapy of supraclavicular lymph node is also rare. All the related reports up to date have mixed them up.

To evaluate the clinical significance and complication of supraclavicular lymph node dissection for breast cancer patients with ipsilateral supraclavicular lymph node metastasis, we randomize patients into two groups, one group is supraclavicular lymph node dissection with radiotherapy group, the other group is radiotherapy group.

Therefore, in addition to investigating the role of surgical removal of the supraclavicular nodes in Chinese patients, we also try to reveal the potential difference between these two treatments, hoping to bring more insight into clinical practice.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 75 Years(Child, Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Ability to understand the study procedures and contents, and willingness to voluntarily sign the written informed consent form;
  • •Age≤75 years old, female;
  • •Histologically confirmed breast cancer;
  • •Histologically or cytologically confirmed ipsilateral supraclavicular lymph node metastasis;
  • •low and moderate risk for anesthesia

排除标准

  • •Absolute and relative contraindication for surgery or radiation;
  • •existing distant metastasis before surgery;
  • •non-invasive breast cancer;
  • •with contralateral breast cancer;
  • •Previous history of breast cancer or other malignancies;
  • •inflammatory breast cancer;
  • •any serious complications which caused patients not suitable to participate this study

研究组 & 干预措施

supraclavicular lymph node dissection and raidiotherapy

Experimental

breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy

干预措施: supraclavicular lymph node dissection (Procedure)

supraclavicular area radiotherapy

Active Comparator

breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy

干预措施: supraclavicular area radiotherapy (Radiation)

结局指标

主要结局

Disease free survival

时间窗: 3-5 years

Disease free survival for 3 years and 5 years, which means the rate of patients without local recurrence and distant metastasis in the whole patients at the same group will be calculated with Kaplan Meier survival curves.

次要结局

  • Life quality score(3-5 years)
  • Recurrence free survival(3-5 years)
  • Occurring rate of complications(3-5 years)
  • Overall survival(3-5 years)

研究者

发起方
Xinhong Wu, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Xinhong Wu, PhD

vice-president

Hubei Cancer Hospital

研究点 (1)

Loading locations...

相似试验